THE WIRE · № 61592
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
01 THE MACHINE READ
WHY IT MATTERS.
Durable two-year psoriasis data supports an oral IL-23R peptide as first-line systemic therapy, strengthening JNJ's immunology franchise against injectable competitors.
Oral psoriasis durability data supports JNJ immunology pipeline
Regulatory filing and approval decisions
Data is company-sponsored, not peer-reviewed
FULL DISPATCH
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 20262026-10-02 11:00 UTC
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals2026-10-02 11:18 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 10:57 UTC
Afya (AFYA) Stock Looks Cheap Following A Fresh Merger Agreement2026-10-02 11:45 UTC
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage2026-10-02 12:15 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.